NHS England/NICE Consultation Could Spell Market Access Complications
Companies with innovative and expensive drugs may face additional hurdles to get their products to the market in England, according to a consultation from NICE, England's health technology appraisal institute, and NHS England.
You may also be interested in...
Office of Health Economics suggests additional criteria could include social preferences on treating patients with very rare diseases, impact beyond direct health benefits, or adjustments for low patient numbers.
As prime minister Theresa May confirms that the UK is to leave the EU single market, the BioIndustry Association has warned that proposals by NICE and NHS England to change funding arrangements for innovative drugs risks impairing the competitiveness of the UK life sciences sector.
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”